Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ting Wang
Institution:
Huazhong Agricultural University
Observed institutions:
Qingdao University,
Huazhong Agricultural University,
Yuhuangding Hospital
ORCID:
0009-0002-1798-562X
Observed ORCID:
0009-0002-1798-562X
OpenAlex ID:
A5072890261
Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023
·
Yifan Liu
, Hongying Wang
, et al.
·
Cancer Research
·
18
IFN-τ Maintains Immune Tolerance by Promoting M2 Macrophage Polarization via Modulation of Bta-miR-30b-5p in Early Uterine Pregnancy in Dairy Cows
2025
·
Xinyu Feng
, Cheng Yang
, et al.
·
Cells
·
8
PDF
Limonin alleviates imiquimod-induced psoriasis-like skin inflammation in mice model by downregulating inflammatory responses
2024
·
Qiang Li
, Fangmei Li
, et al.
·
Naunyn-Schmiedeberg s Archives of Pharmacology
·
8
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023
·
Yifan Liu
, Hongying Wang
, et al.
·
1
Figure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025
·
Yifan Liu
, Hongying Wang
, et al.
Figure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Figure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Figure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025
·
Yifan Liu
, Hongying Wang
, et al.
Figure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Figure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025
·
Yifan Liu
, Hongying Wang
, et al.
Figure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Figure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Figure S8 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
Figure S6 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Figure S7 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
Figure S3 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
Figure S4 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
Figure S5 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Figure S2 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Figure S1 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
PDF
Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
Figure S6 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
Figure S7 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024
·
Yifan Liu
, Hongying Wang
, et al.
Show more works
View as search
Works count:
48
Citation count:
35
H-index:
3
I10-index:
1
Year
Topic
Type